BioCentury
ARTICLE | Financial News

Tasly invests in PegBio's series E round

July 21, 2017 12:57 AM UTC

PegBio Co. Ltd. (Suzhou, China) raised $20 million from Tasly Pharmaceutical Co. Ltd. (Shanghai:600535) in a tranched series E round. CEO Michael Xu told BioCentury that Tasly is the round's lead investor, but declined to disclose its total amount. Existing investor Legend Star also invested in the round, which Xu said he hopes PegBio can complete by September...

BCIQ Company Profiles

PegBio Co. Ltd.